Hypoadiponectinemia and Endogenous Nitric Oxide Synthase Inhibitor in Hypertension.
Wenjuan Xing,Lele Ji,Youyou Li,Feng Gao,Wenjun Yan,Peilin Liu,Lu Sun,Ling Tao,Haifeng Zhang
DOI: https://doi.org/10.1161/hypertensionaha.113.01641
IF: 9.8968
2013-01-01
Hypertension
Abstract:HomeHypertensionVol. 62, No. 2Hypoadiponectinemia and Endogenous Nitric Oxide Synthase Inhibitor in Hypertension Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBHypoadiponectinemia and Endogenous Nitric Oxide Synthase Inhibitor in Hypertension Kazushi Tsuda Kazushi TsudaKazushi Tsuda Cardiovascular and Metabolic Research Center, Kansai University of Health Sciences, Osaka, Japan Search for more papers by this author Originally published10 Jun 2013https://doi.org/10.1161/HYPERTENSIONAHA.113.01641Hypertension. 2013;62:e4Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: January 1, 2013: Previous Version 1 To the Editor:We read with great interest the article by Xing et al1 dealing with the relationship between adiponectin and vascular insulin resistance in hypertension. The results of their study demonstrated that hypoadiponectinemia induced vascular insulin resistance in young spontaneously hypertensive rats. In addition, the authors indicated that downregulation of APPL1 (an adaptor protein that interacts directly with adiponectin receptors by the phosphotyrosine-binding domain) might partially contribute to vascular insulin resistance by differentially modulating the activation of Akt-dependent nitric oxide (NO) and ERK1/2-dependent endothelin-1 pathways in vascular endothelium in spontaneously hypertensive rats. Furthermore, the authors proposed that supplementation with exogenous adiponectin may have potential therapeutic value in the prevention and alleviation of endothelial dysfunction and vascular insulin resistance in hypertension.Current evidence indicates that adiponectin may improve NO bioavailability and restore endothelial dysfunction. In a study presented previously, we investigated the relationship between plasma adiponectin levels and plasma NO metabolites in hypertensive subjects.2 It was demonstrated that plasma adiponectin levels were significantly correlated with plasma NO metabolites.2 In the separate series of the study, we reported that reduced membrane fluidity of red blood cells was associated with hypoadiponectinemia in hypertensive subjects.3 Reduced membrane fluidity of red blood cells might cause a disturbance in the blood rheological behavior and microcirculation, which could contribute, at least in part, to the pathophysiology of circulatory disorders. It might be possible that adiponectin would be a defense against vascular complications in circulatory disorders through increased NO production.However, it has been shown that, in an in vitro study, adiponectin significantly inhibited the tumor necrosis factor-α–induced asymmetrical dimethylarginine (an endogenous NO synthase inhibitor) accumulation in both human umbilical vein endothelial cells and human coronary artery endothelial cells, which was accompanied by an increase in dimethylarginine dimethylaminohydrolase activity.4 Heilman et al5 also have reported the elevated plasma adiponectin and decreased plasma asymmetrical dimethylarginine levels in children with type 1 diabetes mellitus. In this context, it is strongly suggested that adiponectin would protect against endothelial dysfunction, at least in part, by influencing asymmetrical dimethylarginine metabolism. Therefore, we would like to know whether asymmetrical dimethylarginine might actively participate in hypoadiponectinemia-induced alterations in NO signaling and vascular insulin resistance in the study of Xing et al. It would be important to assess more precisely the relationships between adiponectin and endogenous NO synthase inhibitors and their role in the progression of endothelial dysfunction and insulin resistance in hypertension.Kazushi TsudaCardiovascular and Metabolic Research CenterKansai University of Health SciencesOsaka, JapanDisclosuresNone.FootnotesLetters to the Editor will be published, if suitable, as space permits. They should not exceed 500 words (typed double-spaced) plus 5 references in length and may be subject to editing or abridgment. References 1. Xing W, Yan W, Liu P, Ji L, Li Y, Sun L, Tao L, Zhang H, Gao F. A novel mechanism for vascular insulin resistance in normotensive young SHRs: hypoadiponectinemia and resultant APPL1 downregulation.Hypertension. 2013; 61:1028–1035.LinkGoogle Scholar2. Tsuda K. Adiponectin and nitric oxide production in normotensive and hypertensive men.Clin Exp Pharmacol Physiol. 2007; 34(suppl 1):S64–S66.CrossrefGoogle Scholar3. Tsuda K. Adiponectin and membrane fluidity of erythrocytes in normotensive and hypertensive men.Obesity (Silver Spring). 2006; 14:1505–1510.CrossrefMedlineGoogle Scholar4. Eid HM, Lyberg T, Arnesen H, Seljeflot I. Insulin and adiponectin inhibit the TNFα-induced ADMA accumulation in human endothelial cells: the role of DDAH.Atherosclerosis. 2007; 194:e1–e8.CrossrefMedlineGoogle Scholar5. Heilman K, Zilmer M, Zilmer K, Kool P, Tillmann V. Elevated plasma adiponectin and decreased plasma homocysteine and asymmetric dimethylarginine in children with type 1 diabetes.Scand J Clin Lab Invest. 2009; 69:85–91.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Abdel-Fadeil M, Abedelhaffez A, Makhlouf H and Al Qirshi G (2017) Obstructive sleep apnea: Influence of hypertension on adiponectin, inflammatory markers and dyslipidemia, Pathophysiology, 10.1016/j.pathophys.2017.08.003, 24:4, (305-315), Online publication date: 1-Dec-2017. Xing W, Ji L, Li Y, Gao F, Yan W, Liu P, Sun L, Tao L and Zhang H (2013) Response to Hypoadiponectinemia and Endogenous Nitric Oxide Synthase Inhibitor in Hypertension, Hypertension, 62:2, (e5-e5), Online publication date: 1-Aug-2013. August 2013Vol 62, Issue 2 Advertisement Article InformationMetrics © 2013 American Heart Association, Inc.https://doi.org/10.1161/HYPERTENSIONAHA.113.01641PMID: 23753414 Originally publishedJune 10, 2013 PDF download Advertisement SubjectsEndothelium/Vascular Type/Nitric Oxide